旨在报告美国大型转诊中心射频消融 (RFA) 治疗 T1 甲状腺乳头状癌 (PTC) 的有效性、安全性和可行性。我们对 8 名在 Mayo Clinic 接受 RFA 治疗 T1 PTC 的患者进行了回顾性研究2020 年 7 月 1 日至 2023 年 2 月 28 日在明尼苏达州罗彻斯特进行。描述了 RFA 技术和麻醉类型。对手术后长达 24 个月的甲状腺功能、消融区变化和不良事件进行分析。研究中纳入的 8 名患者中，7 名女性，1 名男性，平均±SD 年龄为 53±16.4 岁。 8 名患者中有 7 名的甲状腺状态未受影响。 RFA 的中位持续时间为 6 分钟（范围为 2 至 14.5 分钟），传递的能量在 25 至 45 W 之间。小 PTC 的平均 ± SD 体积为 0.3±0.2 mL，平均最大直径为 9.5±3.3 mm （范围，6 至 15 毫米）。 3至6个月时的平均±SD消融体积大于目标病变（0.8±0.7 mL），7至12个月时平均±SD消融体积减少0.4±0.4 mL，13个月时平均±SD消融体积减少0.1±0.06 mL至 18 个月。消融区在19至24个月时几乎消失（0.04±0.04 mL）。 RFA 手术期间或之后没有发生重大不良事件。这是美国第一个报道的采用 RFA 治疗的 T1 PTC 系列。早期消融后成像显示消融区域大于目标病灶，随后尺寸连续减小。因此，在具有此类专业知识的中心进行 RFA 似乎是治疗小型 PTC 的安全有效的方法。需要进一步的研究来评估其长期疗效和复发风险。版权所有 © 2024 梅奥医学教育和研究基金会。由爱思唯尔公司出版。保留所有权利。

To report the efficacy, safety, and feasibility of radiofrequency ablation (RFA) for T1 papillary thyroid carcinoma (PTC) in a large referral center in the United States.We conducted a retrospective study of 8 patients who underwent RFA for T1 PTC at Mayo Clinic in Rochester Minnesota, between July 1, 2020, and February 28, 2023. The RFA technique and the type of anesthesia are described. Thyroid function, changes in ablated zone, and adverse events were analyzed for up to 24 months after the procedure.Of the 8 patients included in the study, 7 were female and 1 was male with a mean ± SD age of 53±16.4 years. Thyroid status was unaffected in 7 of the 8 patients. The median duration of RFA was 6 minutes (range, 2 to 14.5 minutes) with energy delivered at between 25 and 45 W. The mean ± SD volume of small PTCs was 0.3±0.2 mL, and the mean largest diameter was 9.5±3.3 mm (range, 6 to 15 mm). The mean ± SD ablated volume at 3 to 6 months was larger than the target lesion (0.8±0.7 mL), with a reduction in mean ± SD ablated volume of 0.4±0.4 mL at 7 to 12 months and 0.1±0.06 mL at 13 to 18 months. The ablated zone almost disappeared at 19 to 24 months (0.04±0.04 mL). There were no major adverse events during or after the RFA procedure.This is the first reported series of T1 PTC treated with RFA in the United States. Early postablation imaging revealed that the ablated region was larger than the target lesions, followed by a serial decrease in size. Therefore, RFA at centers with such expertise appears to be a safe and effective treatment for small PTCs. Further studies are needed to evaluate its long-term efficacy and the risk of recurrence.Copyright © 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.